CRM
Why Is Salesforce Stock Surging on Thursday?
Why Is Salesforce Stock Surging on Thursday?...
Financial News Archive
SEC EDGAR · Federal Reserve · FDA · BLS · Updated every 60s
NKE
Wolfe Research Initiates Coverage On Nike with Underperform Rating, Announces Price Target of $28
Wolfe Research Initiates Coverage On Nike with Underperform Rating, Announces Price Target of $28...
DOW
Dow Warns High Interest Rates and Weak Consumer Confidence Are Hurting Housing Demand
Dow Warns High Interest Rates and Weak Consumer Confidence Are Hurting Housing Demand...
IBM
BMO Capital Maintains Market Perform on IBM, Raises Price Target to $265
BMO Capital Maintains Market Perform on IBM, Raises Price Target to $265...
META
Meta Tumbles 6% on AI Spending Fears, 10-Year Yield Falls Below 5%: Stock Market Today
Meta Tumbles 6% on AI Spending Fears, 10-Year Yield Falls Below 5%: Stock Market Today...
PG
QUICK SPARK: Procter & Gamble Stock Eyes Best Day Since 2020 – The Rally Is Hiding Something Bigger
QUICK SPARK: Procter & Gamble Stock Eyes Best Day Since 2020 – The Rally Is Hiding Something Bigger...
IBM
Morgan Stanley Maintains Equal-Weight on IBM, Raises Price Target to $240
Morgan Stanley Maintains Equal-Weight on IBM, Raises Price Target to $240...
JBLU
10 Industrials Stocks With Whale Alerts In Today’s Session
10 Industrials Stocks With Whale Alerts In Today’s Session...
AMZN
10 Consumer Discretionary Stocks Whale Activity In Today’s Session
10 Consumer Discretionary Stocks Whale Activity In Today’s Session...
AAPL
10 Information Technology Stocks With Whale Alerts In Today’s Session
10 Information Technology Stocks With Whale Alerts In Today’s Session...
TSLA
'Intel Plus Elon' Could Pose Bigger Threat to TSMC Than Musk Alone, Chip Analyst Says
'Intel Plus Elon' Could Pose Bigger Threat to TSMC Than Musk Alone, Chip Analyst Says...
NKE
Guggenheim Reiterates Buy on Nike, Maintains $50 Price Target
Guggenheim Reiterates Buy on Nike, Maintains $50 Price Target...
CRM
'Salesforce Customers Brace For New Fees to Use Claude in Its Apps' - The Information
'Salesforce Customers Brace For New Fees to Use Claude in Its Apps' - The Information...
IBM
These Analysts Boost Their Forecasts On IBM Following Upbeat Q3 Results
These Analysts Boost Their Forecasts On IBM Following Upbeat Q3 Results...
PEP
PepsiCo Strikes Back After KFC Loss, Locks In Taco Bell Beverage Deal Through 2036
PepsiCo Strikes Back After KFC Loss, Locks In Taco Bell Beverage Deal Through 2036...
SAGT
Shares of enterprise software companies are trading higher as investors rotate out of highly leveraged AI-exposed stocks and into established technology services companies. Also, SAP and IBM reported better-than-expected Q3 financial results, supporting sentiment toward the sector.
Shares of enterprise software companies are trading higher as investors rotate out of highly leveraged AI-exposed stocks and into established technolo...
QCOM
Shares of semiconductor and chip companies are trading lower amid concerns that mounting AI infrastructure costs could slow future spending and weigh on chip demand. Nvidia CEO Jensen Huang highlighted a scarcity of capital to fund AI expansion, raising concerns that companies could scale back chip purchases, while Lam Research warned that supply chain constraints could delay equipment shipments until March, potentially limiting chipmakers' ability to increase production.
Shares of semiconductor and chip companies are trading lower amid concerns that mounting AI infrastructure costs could slow future spending and weigh ...
MRNA
Why Is Moderna Stock Sinking Thursday?
Why Is Moderna Stock Sinking Thursday?...
INVH
Reported Earlier, U.S. Treasury Department Issues Proposed Regulations To Make Homeownership More Affordable; From January 7, 2027, Large Institutional Investors Generally May Not Purchase A Single-Family Home
Reported Earlier, U.S. Treasury Department Issues Proposed Regulations To Make Homeownership More Affordable; From January 7, 2027, Large Institutiona...
MRK
Merck And Moderna Report Phase 3 Melanoma Trial Results For Personalized mRNA Cancer Therapy; Intismeran Plus KEYTRUDA Cuts Melanoma Recurrence Or Death Risk By 42%
Merck And Moderna Report Phase 3 Melanoma Trial Results For Personalized mRNA Cancer Therapy; Intismeran Plus KEYTRUDA Cuts Melanoma Recurrence Or Dea...